Immunogenicity and Safety of ADACEL™ (TdcP Vaccine) as Fifth Dose in Children 6-8 Years of Age.

Trial Profile

Immunogenicity and Safety of ADACEL™ (TdcP Vaccine) as Fifth Dose in Children 6-8 Years of Age.

Completed
Phase of Trial: Phase III

Latest Information Update: 04 Apr 2014

At a glance

  • Drugs DTaP vaccine (Primary)
  • Indications Diphtheria; Pertussis; Tetanus
  • Focus Pharmacodynamics
  • Sponsors Sanofi
  • Most Recent Events

    • 16 Jun 2009 Actual number of patients (115), official title added as reported by ClinicalTrials.gov.
    • 09 Dec 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 18 Sep 2006 Status change
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top